ABBV and PFE Related Headlines
Go Back- U.S. biopharma earnings: Eli Lilly (LLY), Pfizer (PFE) take the stage
- Health officials explore restrictions on certain SSRI antidepressants - Reuters
- Barclays launches U.S. biopharma coverage with four preferred picks
- Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight
- Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight
- Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight
- Eli Lilly, Pfizer, AbbVie drugs targeted in third Medicare price talks
- Trump to announce prescription drug price agreements
- Bernstein on IRA pricing: $245 really is the floor
ABBV and PFE Related Press Releases
Go Back- Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight
- Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight
- Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight
